InterMune watched its shares jump more than 15% after Boehringer Ingelheim posted some mixed results for its rival idiopathic pulmonary fibrosis treatment, all while the biotech has nearly tripled in value over the past 30 days.
The team concluded that a protein called REST--particularly active in the brains of fetuses and now emerging as a key gene regulator in older brains--also appears to protect neurons in the elderly.
Pfizer picked up the FDA's breakthrough therapy designation for an in-development vaccine against meningococcal disease, a common cause of meningitis, lighting the path for an accelerated approval as the drugmaker looks to expand its vaccine portfolio beyond the blockbuster Prevnar 13.
A week after the FDA put a halt to Geron's in-house studies of the cancer drug imetelstat over toxicity concerns, the agency stepped in on a Mayo Clinic-run trial of the same treatment, citing familiar dangers and imposing a partial clinical hold.
Nonprofit Cancer Research UK is developing a good track record in gamification. In the 18 months since it introduced "Cell Slider," citizen scientists have analyzed more than two million images of tumor samples, and it is now reporting strong uptake of its new mobile game.
Corning is the lead investor in NinePoint Medical's newly nailed-down $34 million Series B round. The 2012 Fierce 15 winner and developer of a cutting-edge organ imaging system also convinced founding investors Third Rock Ventures and Prospect Venture Partners to take part in the company's latest financing.
The first two days of trading passed uneventfully, with Circassia's stock fluctuating around the 310 pence ($5.20) per share price it commanded in the IPO to close on Wednesday at 309 pence.
AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.
Governments around the world have been stockpiling Roche's Tamiflu to protect their citizens in the event of a flu pandemic--a practice that has been questioned by critics who say there's not enough evidence the drug works. Now, Roche has fresh data showing Tamiflu saved lives during the H1N1 swine flu outbreak of 2009.
A British pound rising against the dollar cut into results at Smiths Group--but its U.S.-based Smiths Medical division, beset by competitors, led the bad-news story in the company's earnings report on the first half of its 2014 fiscal year.